Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆

Autor: Michael Millward, V. Atkinson, Sandip Pravin Patel, Christoph Hoeller, Christian U. Blank, Andrew Haydon, Alexander N. Shoushtari, Reinhard Dummer, Alexander M. Menzies, James Larkin, Carina N. Owen, Arissa Young, Maartje W. Rohaan, Dharmisha Chauhan, Shahneen Sandhu, Douglas B. Johnson, J. Mangana, Georgina V. Long, D. Palmieri, Matteo S. Carlino, Serigne Lo, Muhammad A. Khattak, Farzana Y Zaman, Peter Hersey, Belinda Lee

Publikováno v: Ann Oncol

Background: Anti-programmed cell death protein 1 (PD-1) antibodies (PD1) prolong recurrence-free survival in high-risk resected melanoma; however, approximately 25%-30% of patients recur within 1 year. This study describes the pattern of recurrence,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b83e339b674f679f965aaea6b9ddf88
https://doi.org/10.1016/j.annonc.2020.04.471

Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma

Autor: N. Thompson, Christian U. Blank, Adnan Khattak, Alice Labianca, A. Arance, T. Quah, Wen Xu, Clara Allayous, C. Martínez-Vila, Ryan J. Sullivan, Roslyn Wallace, P.A. Ascierto, Sarah J. Welsh, Carina N. Owen, Shahneen Sandhu, Prachi Bhave, V. Vanella, Xue Bai, Jennifer L. McQuade, Céleste Lebbé, Bart Neyns, Matteo S. Carlino, Irene L.M. Reijers, J. Mangana, Serigne Lo, Sophia Callaghan, Mario Mandalà, Sandrine Aspeslagh, Olivier Michielin, Camille L. Gerard, Paul Lorigan, Douglas B. Johnson, Andrew Haydon, Lisa Zimmer, Georgina V. Long, A.M. Menzies

Publikováno v: Owen, C N, Bai, X, Quah, T, Lo, S N, Allayous, C, Callaghan, S, Martínez-Vila, C, Wallace, R, Bhave, P, Reijers, I L M, Thompson, N, Vanella, V, Gerard, C L, Aspeslagh, S, Labianca, A, Khattak, A, Mandala, M, Xu, W, Neyns, B, Michielin, O, Blank, C U, Welsh, S J, Haydon, A, Sandhu, S, Mangana, J, McQuade, J L, Ascierto, P A, Zimmer, L, Johnson, D B, Arance, A, Lorigan, P, Lebbé, C, Carlino, M S, Sullivan, R J, Long, G V & Menzies, A M 2021, ' Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma ', Annals of Oncology, vol. 32, no. 7, pp. 917-925 . https://doi.org/10.1016/j.annonc.2021.03.204

BACKGROUND: Immune-related adverse events (irAEs) typically occur within 4 months of starting anti-programmed cell death protein 1 (PD-1)-based therapy [anti-PD-1 ± anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4)], but delayed irAEs (onset

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13b5c19117384b568cfd2a11dbc3489c
http://hdl.handle.net/11391/1491436

A multicenter analysis of melanoma recurrence following adjuvant anti-PD1 therapy

Autor: Joanna Mangana, James Larkin, Farzana Y Zaman, Michael Millward, Christian U. Blank, Peter Hersey, Alexander N. Shoushtari, Belinda Lee, Christoph Hoeller, D. Palmieri, Matteo S. Carlino, Arissa Young, Carina N. Owen, Muhammad A. Khattak, Georgina V. Long, Alexander M. Menzies, Dharmisha Chauhan, Sapna Pradyuman Patel, Serigne Lo, Victoria Atkinson

Publikováno v: Journal of Clinical Oncology. 37:9502-9502

9502 Background: Adjuvant anti-PD1 monoclonal antibodies (mAbs) prolong recurrence-free survival in high-risk resected melanoma, however patients (pts) recur during or after therapy. The patterns of recurrence and optimal management are unclear. Meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d539009156bd097089572da2c782010
https://doi.org/10.1200/jco.2019.37.15_suppl.9502

Outcome of patients with elevated LDH treated with first-line targeted therapy (TT) or PD-1 based immune checkpoint inhibitors (ICI)

Autor: Ralf Gutzmer, Carsten Weishaupt, Jessica C. Hassel, Katharina C. Kähler, Lisa Zimmer, S. Knispel, Maria I. Schmidgen, Christopher G. Cann, Dennis Niebel, Patrick Schummer, Dirk Schadendorf, Douglas B. Johnson, Thomas Eigentler, Cindy Franklin, Carmen Loquai, Felix Kiecker, Peter Mohr, M. Gassenmaier, A.M. Menzies, Carina N. Owen

Publikováno v: Web of Science

Background Elevated LDH is a known predictive and prognostic factor correlating with poor response rates and survival in patients (pts) with metastatic melanoma (MM) treated with targeted therapy (BRAF plus MEK inhibitors, TT) or immune checkpoint in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc3815fe3324c972663d533f7d250ad
https://publons.com/wos-op/publon/27728529/